Komori
General Meetings of Shareholders4502Takeda Pharmaceutical Company LimitedPharmaceuticals

Planned Amendments to the Consolidated Financial Statements Relating to Subsequent Events

Following the jury verdict in the U.S. antitrust litigation concerning AMITIZA®, the company plans to amend its earnings summary for the fiscal year ended March 2026 and other earnings materials. The amount of the impact is currently under review, and the earnings forecast and management guidance will also be amended as necessary.

Worth reading
—
Scored from 0 of 4 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Resolutions for the General Meeting of Shareholders
ItemDetails
Items this document does not state (6)
Type of shareholders' meetingDate and timeMatters for resolutionShareholder ProposalDirector nomineePercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The jury verdict on 18 May 2026 constitutes an adjusting subsequent event in the earnings summary for the fiscal year ended March 2026. As the event occurred after the date of the audit report for the Companies Act audit, it will not be reflected in the consolidated financial statements or the financial statements prepared under the Companies Act.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Planned Amendments to the Consolidated Financial Statements Relating to Subsequent Events | Takeda Pharmaceutical Company Limited (4502) timely disclosure | Komori